Trial Profile

A Multicenter, Open-label, Phase II Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLC

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rilertinib (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Sponsors Nanjing Sanhome Pharmaceutical

Most Recent Events

04 Jul 2022 Status changed from recruiting to completed, according to Results published in the Journal of Thoracic Oncology.
04 Jul 2022 Results assessing efficacy and safety of SH-1028 in non-small-cell lung cancer patients, published in the Journal of Thoracic Oncology.
14 Sep 2021 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com